Chinese maker of active pharmaceutical ingredients and generic formulations, a major API exporter to the US and European generics markets.
Chinese maker of active pharmaceutical ingredients and generic formulations, a major API exporter to the US and European generics markets.
Sells active ingredients to generic-drug makers worldwide, including the US and Europe, and finished generics under its own filings, so approvals by the FDA and EU regulators decide what it can ship. A 2018 impurity found in its valsartan ingredient led to recalls and regulatory action, and quality compliance has weighed on the business since.
Moat: narrow (regulatory licence, scale). FDA/EU-approved API facilities and a large ANDA portfolio, though past quality lapses have hurt trust.
Headquarters: Linhai, Zhejiang, China · Employees: 8,797
Size Zhejiang Huahai Pharmaceutical (600521.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.61B, the 668th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.48 on 18 Nov 2026.
Performance Over six months the shares fell 0.2%, against +8.1% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 10.3% over the last twelve months (peer median +11.9%); the operating margin is 12.2% (peer median 16.8%).
Valuation It trades at 20.1× forward earnings against a peer median of 20.7× (7th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.0 points above its cost of capital (6.6% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥9.60B | CN¥8.54B | CN¥9.49B | CN¥8.26B | CN¥8.23B |
| Revenue growth | — | -10% | +15% | 0% | — |
| Gross profit | CN¥6.13B | CN¥4.70B | CN¥5.50B | CN¥4.68B | CN¥4.88B |
| EBITDA | n/a | CN¥1.59B | CN¥2.49B | CN¥2.08B | CN¥2.20B |
| Net income | CN¥946M | CN¥266M | CN¥1.12B | CN¥830M | CN¥1.17B |
| Free cash flow | CN¥249M | -CN¥734M | CN¥320M | CN¥630M | -CN¥1.07B |
| Capital expenditure | CN¥1.86B | CN¥1.97B | CN¥1.85B | CN¥1.59B | CN¥2.32B |
| Total debt | CN¥8.94B | CN¥8.66B | CN¥8.07B | CN¥7.45B | CN¥7.42B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% |
| Apeloa Pharmaceutical 000739.SZ | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% |
| Zhejiang Hisun Pharmaceutical 600267.SS | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% |
| Zhejiang Xianju Pharmaceutical 002332.SZ | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% |
| Zhejiang Medicine 600216.SS | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% |
| Aurobindo Pharma AUROPHARMA.NS | $11.0B | +19% | +14% | 15% | 22.3× | 21.1% |
| Dr. Reddy's Laboratories DRREDDY.NS | $12.5B | +5% | -4% | 9% | 32.0× | 30.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600521.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.6% | +4.5% | 9th lowest of 21 |
| 6-month return | -0.2% | +8.1% | 9th lowest of 20 |
| Distance from 52-week high | -13.9% | -23.4% | 6th highest of 21 |
| Revenue growth (TTM) | +10.3% | +11.9% | 10th highest of 19 |
| Operating margin | 12.2% | 16.8% | 7th lowest of 17 |
| Forward P/E | 20.1× | 20.7× | 7th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | 6.4% | 0.9% | 5th most demanding of 12 |
| Growth delivered (Del g) | +5.9% | +10.6% | 5th lowest of 12 |
| Hurdle (Req g minus delivered) | +0.5 pp | -12.7 pp | 3rd most demanding of 12 |
| ROIC minus cost of capital | +2.0 pp | +5.6 pp | 7th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Livzon Pharmaceutical 1513.HK | Hong Kong | $3.73B | -9% | -10% | 19% | 11.3× | -7.0% | +2.0% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | n/a | 34.7% | +159.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 21.9× | 1.2% | +12.1% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 28.5× | 16.2% | -5.8% |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% | +45.1% |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |